一名患有十二指肠神经内分泌肿瘤肝和骨转移的 76 岁女性接受了 177Lu-DOTATATE 肽受体放射性核素治疗。治疗后 4 天进行的 SPECT/CT 闪烁扫描显示 177Lu-DOTATATE 摄取表现为双侧肺部多灶性磨玻璃样混浊。这种吸收被认为是由于 COVID-19 肺炎所致，因为患者在治疗前 7 天感染了该病毒。第二次治疗后两个月后，肺部混浊变小，显示摄取减少。 177Lu-DOTATATE 可以在 COVID-19 肺炎活跃期服用。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.